Avalo Therapeutics, Inc. (AVTX)

Avalo Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 12, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Cap	309	78	7	48	192	198
Market Cap Growth	310.28%	966.44%	-84.65%	-75.21%	-3.16%	-17.23%
Enterprise Value	198.29	-56.74	-0.12	53.77	169.99	179.09
Last Close Price	16.71	7.43	9.10	1209.60	4896.00	7603.20
PE Ratio	-	-0.36	-0.08	-1.14	-2.05	-3.03
PS Ratio	1611.19	176.43	3.79	2.63	35.52	29.56
PB Ratio	3.25	0.58	1.00	-4.35	8.31	8.06
P/TBV Ratio	853.14	0.21	0.35	-4344.36	7.12	7.12
P/FCF Ratio	-	-1.59	-0.24	-1.77	-2.70	-4.88
P/OCF Ratio	-	-1.59	-0.24	-1.78	-2.70	-4.88
EV/Sales Ratio	1032.74	-128.66	-0.06	2.98	31.49	26.73
EV/EBITDA Ratio	-	0.83	0.00	-1.44	-2.11	-2.52
EV/EBIT Ratio	-	0.83	0.00	-1.44	-2.07	-2.46
EV/FCF Ratio	-	1.16	0.00	-2.00	-2.39	-4.41
Debt / Equity Ratio	-	0	0	-1.78	1.42	0
Debt / EBITDA Ratio	-	-	-	-0.52	-0.41	-
Debt / FCF Ratio	-	-	-	-0.72	-0.46	-
Net Debt / Equity Ratio	-1.22	-1.01	-1.01	-0.57	-0.94	-0.77
Net Debt / EBITDA Ratio	1.69	1.97	0.27	-0.17	0.27	0.27
Net Debt / FCF Ratio	2.14	2.74	0.24	-0.23	0.31	0.47
Asset Turnover	0.00	0.01	0.07	0.32	0.09	0.17
Inventory Turnover	-	-	128.40	118.41	72.73	24.66
Quick Ratio	14.00	19.33	1.64	0.68	2.99	1.53
Current Ratio	14.28	19.96	1.82	0.74	3.11	1.71
Return on Equity (ROE)	-88.95%	-50.06%	1747.11%	-684.77%	-354.08%	-282.65%
Return on Assets (ROA)	-48.29%	-80.05%	-100.67%	-65.97%	-132.20%	-174.83%
Return on Invested Capital (ROIC)	-882.21%	-741.24%	-419.07%	-761.49%	-981.77%	-390.75%
Return on Capital Employed (ROCE)	-50.97%	-85.56%	-197.99%	-104.61%	-184.87%	-277.61%
Earnings Yield	-32.23%	-281.43%	-1248.13%	-87.88%	-48.77%	-32.95%
FCF Yield	-16.89%	-63.05%	-422.68%	-56.48%	-37.03%	-20.51%
Buyback Yield / Dilution	0.07%	-237.86%	-634.41%	30.93%	-38.52%	-22.62%

Updated Nov 6, 2025. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q